206 related articles for article (PubMed ID: 37834346)
1. The cGAS/STING/IFN-1 Response in Squamous Head and Neck Cancer Cells after Genotoxic Challenges and Abrogation of the ATR-Chk1 and Fanconi Anemia Axis.
Zahnreich S; El Guerzyfy S; Kaufmann J; Schmidberger H
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834346
[TBL] [Abstract][Full Text] [Related]
2. cGAS-STING responses are dampened in high-risk HPV type 16 positive head and neck squamous cell carcinoma cells.
Shaikh MH; Bortnik V; McMillan NA; Idris A
Microb Pathog; 2019 Jul; 132():162-165. PubMed ID: 31054871
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.
Karukonda P; Odhiambo D; Mowery YM
Mol Carcinog; 2022 Feb; 61(2):225-238. PubMed ID: 34964992
[TBL] [Abstract][Full Text] [Related]
4. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
5. Caspase activation counteracts interferon signaling after G2 checkpoint abrogation by ATR inhibition in irradiated human cancer cells.
Eek Mariampillai A; Hauge S; Øynebråten I; Rødland GE; Corthay A; Syljuåsen RG
Front Oncol; 2022; 12():981332. PubMed ID: 36387237
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract][Full Text] [Related]
7. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
8. Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers.
Dok R; Glorieux M; Bamps M; Nuyts S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546122
[TBL] [Abstract][Full Text] [Related]
9. Generating New FANCA-Deficient HNSCC Cell Lines by Genomic Editing Recapitulates the Cellular Phenotypes of Fanconi Anemia.
Errazquin R; Sieiro E; Moreno P; Ramirez MJ; Lorz C; Peral J; Ortiz J; Casado JA; Roman-Rodriguez FJ; Hanenberg H; Río P; Surralles J; Segrelles C; Garcia-Escudero R
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918752
[TBL] [Abstract][Full Text] [Related]
10. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.
Hess J; Unger K; Orth M; Schötz U; Schüttrumpf L; Zangen V; Gimenez-Aznar I; Michna A; Schneider L; Stamp R; Selmansberger M; Braselmann H; Hieber L; Drexler GA; Kuger S; Klein D; Jendrossek V; Friedl AA; Belka C; Zitzelsberger H; Lauber K
Cancer Lett; 2017 Feb; 386():87-99. PubMed ID: 27867017
[TBL] [Abstract][Full Text] [Related]
11. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract][Full Text] [Related]
12. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
13. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA PANDAR promoted radiation and cisplatin-induced DNA damage repair through ATR/CHK1 in NSCLC.
Zhao S; Yu N; Wang H; Wan Z; Diao C; Chen Y; Liu T; Yang Y; Gao F; Bai C; Cao K; Cai J
J Gene Med; 2023 Dec; 25(12):e3565. PubMed ID: 37460393
[TBL] [Abstract][Full Text] [Related]
15. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition.
Li X; Li Y; Zhao Z; Miao N; Liu G; Deng L; Wei S; Hou J
Cancer Med; 2023 Feb; 12(4):4864-4881. PubMed ID: 35957613
[TBL] [Abstract][Full Text] [Related]
17. ATR promotes clearance of damaged DNA and damaged cells by rupturing micronuclei.
Joo YK; Black EM; Trier I; Haakma W; Zou L; Kabeche L
Mol Cell; 2023 Oct; 83(20):3642-3658.e4. PubMed ID: 37788673
[TBL] [Abstract][Full Text] [Related]
18. Manganese facilitated cGAS-STING-IFNI pathway activation induced by ionizing radiation in glioma cells.
He Y; Yang Y; Huang W; Yang S; Xue X; Zhu K; Tan H; Sun T; Yang W
Int J Radiat Biol; 2023; 99(12):1890-1907. PubMed ID: 37406172
[TBL] [Abstract][Full Text] [Related]
19. HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1.
Busch CJ; Kriegs M; Laban S; Tribius S; Knecht R; Petersen C; Dikomey E; Rieckmann T
Radiother Oncol; 2013 Sep; 108(3):495-9. PubMed ID: 23932155
[TBL] [Abstract][Full Text] [Related]
20. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
McLaughlin M; Barker HE; Khan AA; Pedersen M; Dillon M; Mansfield DC; Patel R; Kyula JN; Bhide SA; Newbold KL; Nutting CM; Harrington KJ
BMC Cancer; 2017 Jan; 17(1):86. PubMed ID: 28143445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
